JPS6366200B2 - - Google Patents

Info

Publication number
JPS6366200B2
JPS6366200B2 JP17806181A JP17806181A JPS6366200B2 JP S6366200 B2 JPS6366200 B2 JP S6366200B2 JP 17806181 A JP17806181 A JP 17806181A JP 17806181 A JP17806181 A JP 17806181A JP S6366200 B2 JPS6366200 B2 JP S6366200B2
Authority
JP
Japan
Prior art keywords
acid
culture
valine
medium
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP17806181A
Other languages
Japanese (ja)
Other versions
JPS5878594A (en
Inventor
Michihisa Ono
Hiroshi Takiguchi
Hiroshi Mishima
Micha Terao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to JP17806181A priority Critical patent/JPS5878594A/en
Publication of JPS5878594A publication Critical patent/JPS5878594A/en
Publication of JPS6366200B2 publication Critical patent/JPS6366200B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は駆虫剤及び殺ダニ剤として有用な抗生
物質B−41D、E及びGを工業的に有利に製造す
る方法に関する。 B−41D、E及びGは、ストレプトマイセス属
に属するB−41生産菌、例えばB−41−146株の
培養によつて得られる抗生物質であつて、次の構
造式を有し、 動物に寄生する蠕虫とくに線虫及び動植物に寄
生するダニの駆除等に有効であることは、特開昭
56−32481号公報、特願昭55−153141号(特開昭
57−77686号)明細書及び特願昭56−7091号(特
開昭57−120589号)明細書に知られている。 ところで、通常の方法でB−41生産菌を培養し
た場合、上記構造式に対応して25位がメチル基で
あるB−41A1、A3、B2及び25位がエチル基であ
るB−41A4、B3、B2などを同時に生産するため、
25位がイソプロピル基である最も活性なB−
41D、E及びGをより収率よく生産する方法が望
まれる。 本発明者等は、B−41生産菌を培養するに際
し、培地に特定の物質を添加することにより、B
−41D、E及びGが高収量で生産されることを見
い出した。 本発明は、ストレプトミセス属に属するB−41
生産菌を培養してB−41D、E及びGを製造する
に際し、バリン、イソ酪酸、イソ吉草酸、2−ケ
トイソ吉草酸、イソカプロン酸、これらの酸の塩
またはエステル、イソブタノール及びそのエステ
ルから選ばれた1種または2種以上を培地に添加
することを特徴とするB−41D、E及びGの製造
法である。 B−41生産菌、例えばストレプトミセス属B−
41−146株は通産省工業技術院微生物工業技術研
究所に微工研条寄第1072号として寄託されてお
り、その菌学的性状は特開昭50−29472号公報に
詳しく記載されている。本発明において使用する
菌には、上記B−41−146株を例えばX線照射、
紫外線照射、放射線照射、人工変異剤を用いて人
工変更したものであつて、B−41D、E及びGの
生産能を有するものは包含される。 本発明の方法において培地中に添加するバリン
はL体又はDLの光学異性体が用いられる。バリ
ン、イソ酪酸、イソ吉草酸、2−ケトイソ吉草
酸、イソカプロン酸のうちではL−またはDLバ
リン、イソ酪酸、2−ケトイソ吉草酸は好適に用
いられる。これらの酸の塩としてはナトリウム
塩、カリウム塩などがあげられ、エステルとして
はメチル、エチル、n−ブチルのような低級アル
キルエステルまたはベンジルエステルがあげられ
る。イソブタノール及びそのエステルも用いるこ
とができ、エステルとしては酢酸、プロピオン酸
のような低級飽和脂肪酸とのエステルがあげられ
る。上記添加物の 13C−ラベル化合物を用いた実
験では生成物の25位にイソプロピル基が特異的に
取り込まれていることが確認された。 培地に対するこれら添加物の添加量は一般的に
は0.001〜1W/V%、好ましくは0.005〜0.01W/
V%が添加される。添加時期は培地の調製時また
は培養中の適宜の段階で添加してもよい。 B−41生産菌の培養に用いられる培地は該微生
物が利用しうる栄養源を含むものならよく、上記
添加物を添加するほか、炭素源としてはグルコー
ス、しよ糖、殿粉、グリセリン、水あめ、糖蜜、
大豆油などが使用され、窒素源としてはスキムミ
ルク、大豆粉、小麦胚芽、肉エキス、ペプトン、
酵母菌体、コーンスチープ・リカー、硫酸アンモ
ニウム、硝酸アンモニウム等が使用される。この
ほか必要に応じて炭酸カルシウム、食塩、塩化カ
リ、リン酸塩類を添加することができる。 培養法としては、一般の抗生物質を生産する方
法と同じく液体培養法、とくに深部培養法が最も
適している。培養は好気的条件下で行なわれ、培
養に適当な温度は22〜30℃であるが多くの場合28
℃付近で培養する。培地の液性は概ねPH5.5〜8.0
の間でよく、望ましくはPH約6.5〜7.5の中性近傍
でよりよい結果をうることができる。培養はB−
41D、EおよびGの蓄積濃度が最大となる迄行な
うが、これに要する時間は、培養の方法、温度、
培地の組成など条件によつて差はあるものの、通
常約5〜15日程度である。 B−41各成分の検定にあたつては次の方法が用
いられる。すなわち、培養物3mlを小試験管にと
り、アセトン7mlを添加振とうして抽出し遠心分
離する。ここで得られた上澄の10〜20μをTLC
用板(メルク社製、Kieselgel 60 F254)上の所
定の位置に吸着せしめ、これをジオキサン:四塩
化炭素(18:82)で4時間展開後、二波長クロマ
トスキヤナを用いて245nmの波長(ブランクは
380nm)で測定し、その吸収量を標準物質のそ
れと比較し、算出する。 B−41D、EおよびGを培養物から採取するに
あたつては、活性炭、アルミナ、シリカゲルなど
の吸着剤、ダイヤイオンHP−10、HP−20(三菱
化成社製)などの合成吸着剤、アビセル(旭化成
社製)、紙などの固定剤、イオン交換樹脂、イ
オン交換ゲル過剤などが使用されうるが、以下
に示す採取方法が最も効果的である。 培養物を、けいそう土などの過助剤を用いて
別し、ここで得られたケーキをメタノール抽出
することにより、目的物はメタノール水に溶解し
てくる。これに水を加えた後、n−ヘキサンで抽
出し、これを減圧下で濃縮することにより、目的
物を含有するオイル状物質が得られる。これをシ
リカゲル(ワコーゲルC−200)のカラムに吸着
せしめ、n−ヘキサン:アセトン(95:5)で溶
出し、B−41Dを含有するフラクシヨン、B−
41Eを含有するフラクシヨンおよびB−41Gを含
有するフラクシヨンを集める。各フラクシヨンは
減圧下で濃縮し、ここで得られた残渣を少量のn
−ヘキサン:酢酸エチル(20:1)に溶解し、室
温に放置するとB−41D、B−41E、B−41Gが
それぞれ結晶状に得られる。 本発明の方法によれば特にB−41D、Eおよび
G成分の生成比率が非常に高く、また生成量も増
大するので、分離精製が容易になり工業生産上き
わめて有利な方法である。 以下実施例を挙げて、本発明を具体的に説明す
る。 実施例 1 種培地(シユクロース1%、ポリペプトン0.35
%、K2HPO40.05%)100mlを500mlエルレンマイ
ヤーフラスコに分注し、滅菌後、B−41−146株
を1白金耳接種し、48時間28℃で培養し、種培養
とした。 この1mlを主培地(グルコース4%、大豆粉1
%、スキムミルク1%、NaCl0.3%、コーンスチ
ープ・リカー0.2%及びCaCO30.05%)20ml含む
100mlエルレンマイヤーフラスコに接種し、28℃
で3日振とう培養したのち、DL−バリン−2−
13Cを0.01W/V%になるように添加し、さらに
2日間培養した。培養終了時、培養物中に生成し
たB−41群抗生物質のうちB−41Dの占める割合
は約65%、Eの割合は18%及びGの割合は5%で
あつた。なお添加物なしに培養したときD、Eお
よびGの占める割合は、それぞれ37%、9%およ
び2%であつた。 DL−バリン−2− 13Cを添加して培養した培
養物を過し、菌体をメタノール抽出した。これ
に水を加えて50%メタノール溶液にし、n−ヘキ
サンで抽出した。得られたn−ヘキサン層は芒硝
で脱水後、減圧下で濃縮し、オイル状物質を得
た。このオイル状物質をシリカゲルカラムさらに
ローバーカラム(メルク社製)で精製し、B−41
物質の各成分を単離した。得られた各成分中の
13Cの取り込みを、400メガヘルツの 13C−NMR
及びマス・スペクトルで測定したところ、DL−
バリン−2− 13Cの 13CがB−41D、EおよびG
のC−25位に特異的に取り込まれている事がわか
つた。 実施例 2 実施例1の種培養物をグルコース6%、アスパ
ラギン0.3%、ロイシン0.5%、リン酸第2カリウ
ム0.05%、硫酸マグネシウム0.05%、食塩0.05%、
塩化カルシウム0.02%、硫酸亜鉛0.005%、硫酸
マンガン0.001%、硫酸第1鉄0.002%及び微量の
ビタミン類からなる培地20mlに1mlづつ接種し、
L−バリン、イソ酪酸、2−ケトイソ吉草酸、イ
ソカプロン酸及びイソブタノールを第1表に示す
条件で添加して、28℃で8日間振とう培養した結
果、第1表に示す結果が得られた。
The present invention relates to an industrially advantageous method for producing antibiotics B-41D, E and G useful as anthelmintics and acaricides. B-41D, E, and G are antibiotics obtained by culturing B-41-producing bacteria belonging to the genus Streptomyces, such as the B-41-146 strain, and have the following structural formula, It has been shown in Japanese Unexamined Patent Application Publication No. 2003-12113 that it is effective in exterminating helminths that parasitize animals, especially nematodes, and mites that parasitize animals and plants.
Publication No. 56-32481, Japanese Patent Application No. 55-153141
57-77686) and Japanese Patent Application No. 56-7091 (Japanese Unexamined Patent Publication No. 57-120589). By the way, when B-41-producing bacteria are cultured in the usual manner, B-41A 1 , A 3 , B 2 having a methyl group at the 25th position and B-41 having an ethyl group at the 25th position correspond to the above structural formula. To produce 41A 4 , B 3 , B 2 , etc. at the same time,
The most active B- with isopropyl group at position 25
A method for producing 41D, E, and G with higher yields is desired. The present inventors have discovered that when culturing B-41-producing bacteria, by adding a specific substance to the medium,
-41D, E and G were found to be produced in high yields. The present invention relates to B-41 which belongs to the genus Streptomyces.
When producing B-41D, E and G by culturing production bacteria, from valine, isobutyric acid, isovaleric acid, 2-ketoisovaleric acid, isocaproic acid, salts or esters of these acids, isobutanol and its esters. This is a method for producing B-41D, E, and G, which is characterized by adding one or more selected types to a medium. B-41 producing bacteria, such as Streptomyces B-
Strain 41-146 has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as FAIKEN Article No. 1072, and its mycological properties are described in detail in JP-A-50-29472. The bacteria used in the present invention include the above B-41-146 strain, for example, by X-ray irradiation,
Those that have been artificially modified using ultraviolet irradiation, radiation irradiation, or artificial mutating agents and that have the ability to produce B-41D, E, and G are included. In the method of the present invention, the L-form or DL optical isomer of valine added to the medium is used. Among valine, isobutyric acid, isovaleric acid, 2-ketoisovaleric acid, and isocaproic acid, L- or DL valine, isobutyric acid, and 2-ketoisovaleric acid are preferably used. Examples of salts of these acids include sodium salts and potassium salts, and examples of esters include lower alkyl esters such as methyl, ethyl, and n-butyl, or benzyl esters. Isobutanol and its esters can also be used, and esters include those with lower saturated fatty acids such as acetic acid and propionic acid. In an experiment using the above additive 13 C-labeled compound, it was confirmed that an isopropyl group was specifically incorporated into the 25th position of the product. The amount of these additives added to the medium is generally 0.001 to 1 W/V%, preferably 0.005 to 0.01 W/V%.
V% is added. The addition time may be during preparation of the medium or at an appropriate stage during culture. The medium used for culturing the B-41-producing microorganisms may be one that contains nutritional sources that can be used by the microorganisms, and in addition to the above additives, carbon sources include glucose, sucrose, starch, glycerin, and starch syrup. , molasses,
Soybean oil is used, and nitrogen sources include skim milk, soybean flour, wheat germ, meat extract, peptone,
Yeast cells, corn steep liquor, ammonium sulfate, ammonium nitrate, etc. are used. In addition, calcium carbonate, common salt, potassium chloride, and phosphates can be added as necessary. The most suitable culture method is the liquid culture method, especially the deep culture method, similar to the method for producing general antibiotics. Cultivation is carried out under aerobic conditions, and the appropriate temperature for cultivation is 22 to 30°C, but in most cases 28°C.
Culture at around ℃. The liquid quality of the medium is approximately PH5.5-8.0
It is best to have a pH between 6.5 and 7.5, preferably around neutral pH, to obtain better results. Culture is B-
The process is continued until the accumulated concentration of 41D, E, and G reaches the maximum, but the time required for this depends on the culture method, temperature,
Although it varies depending on conditions such as the composition of the medium, it usually takes about 5 to 15 days. B-41 The following method is used to test each component. That is, 3 ml of the culture is placed in a small test tube, 7 ml of acetone is added, shaken, extracted, and centrifuged. TLC 10-20μ of the supernatant obtained here.
The sample was adsorbed onto a predetermined position on a commercial plate (Merck, Kieselgel 60 F 254 ), developed with dioxane:carbon tetrachloride (18:82) for 4 hours, and then exposed to a wavelength of 245 nm using a dual wavelength chromatography scanner. (The blank is
380nm), and the absorption amount is compared with that of the standard substance and calculated. When collecting B-41D, E, and G from cultures, adsorbents such as activated carbon, alumina, and silica gel, synthetic adsorbents such as Diaion HP-10 and HP-20 (manufactured by Mitsubishi Chemical Corporation), Avicel (manufactured by Asahi Kasei Corporation), a fixing agent such as paper, an ion exchange resin, an ion exchange gel filter, etc. can be used, but the collection method shown below is the most effective. The target product is dissolved in methanol water by separating the culture using a supernatant such as diatomaceous earth and extracting the resulting cake with methanol. After adding water to this, extraction is performed with n-hexane, and this is concentrated under reduced pressure to obtain an oily substance containing the target product. This was adsorbed on a column of silica gel (Wako Gel C-200) and eluted with n-hexane:acetone (95:5) to obtain a fraction containing B-41D.
Collect the fraction containing 41E and the fraction containing B-41G. Each fraction was concentrated under reduced pressure and the resulting residue was added to a small amount of n
- When dissolved in hexane:ethyl acetate (20:1) and allowed to stand at room temperature, B-41D, B-41E, and B-41G are obtained in crystalline form, respectively. According to the method of the present invention, the production ratio of B-41D, E, and G components in particular is very high, and the amount produced is also increased, making separation and purification easy, making it an extremely advantageous method for industrial production. The present invention will be specifically described below with reference to Examples. Example 1 Seed medium (sucrose 1%, polypeptone 0.35
%, K 2 HPO 4 0.05%) was dispensed into a 500 ml Erlenmeyer flask, and after sterilization, one loopful of strain B-41-146 was inoculated and cultured at 28° C. for 48 hours to serve as a seed culture. Add 1 ml of this to main medium (4% glucose, 1 ml of soybean flour)
%, skim milk 1%, NaCl 0.3%, corn steep liquor 0.2% and CaCO 3 0.05%) 20ml
Inoculate a 100ml Erlenmeyer flask and incubate at 28°C.
After shaking culture for 3 days, DL-valine-2-
13 C was added at a concentration of 0.01 W/V%, and the cells were cultured for an additional 2 days. At the end of the culture, of the B-41 group antibiotics produced in the culture, B-41D accounted for approximately 65%, E accounted for 18%, and G accounted for 5%. When cultured without additives, the proportions of D, E, and G were 37%, 9%, and 2%, respectively. A culture cultured with the addition of DL-valine- 2-13C was filtered, and the bacterial cells were extracted with methanol. Water was added to this to make a 50% methanol solution, and the mixture was extracted with n-hexane. The obtained n-hexane layer was dehydrated with Glauber's salt and concentrated under reduced pressure to obtain an oily substance. This oily substance was purified using a silica gel column and a Lorber column (manufactured by Merck & Co.), and B-41
Each component of the material was isolated. In each component obtained
13C uptake was performed using 13C -NMR at 400 MHz.
When measured by mass spectrometry, DL−
Valine-2- 13 C of 13 C is B-41D, E and G
It was found that the protein was specifically incorporated into the C-25 position. Example 2 The seed culture of Example 1 was mixed with 6% glucose, 0.3% asparagine, 0.5% leucine, 0.05% dipotassium phosphate, 0.05% magnesium sulfate, 0.05% salt,
Inoculate 1 ml each into 20 ml of a medium consisting of 0.02% calcium chloride, 0.005% zinc sulfate, 0.001% manganese sulfate, 0.002% ferrous sulfate, and trace amounts of vitamins.
L-valine, isobutyric acid, 2-ketoisovaleric acid, isocaproic acid, and isobutanol were added under the conditions shown in Table 1, and cultured with shaking at 28°C for 8 days. As a result, the results shown in Table 1 were obtained. Ta.

【表】 実施例 3 実施例1に示した種培地を調製し、その600ml
を2000mlエルレンマイヤーフラスコに分注し、滅
菌した。これにB−41−146株を1白金耳接種し、
48時間28℃で培養を行ない、この2000mlエルレン
マイヤーフラスコ2本を30ジヤー・フアメンタ
に移植した。ジヤー・フアメンタには、グルコー
ス4%、大豆粉1%、コーンスターチ0.5%、ス
キムミルク1%、コーンスチープ・リカー0.2%、
食塩0.3%及びCaCO30.05%を含有する培地20
を仕込み、PHを7.2〜7.5に調節し、十分に滅菌し
ておいた。培養期間中は、28℃、内圧0.5Kg/cm2
に保持した。3日培養後DL−バリンを0.01%添
加しさらに5日間培養した。B−41群抗生物質総
生産量のうちDは68%(重量比)の割合を占め
た。同条件でDL−バリンを添加せず培養した場
合には、B−41Dの割合は35%にとどまつた。
DL−バリンを添加して得られた培養物20のPH
を硫酸で3とし、セライト1Kgを加えて加圧過
すると約3Kgのケーキが得られた。これを15の
メタノールで抽出し、別し、得られたメタノー
ル溶液15に水10を加え、20のn−ヘキサン
で抽出した。得られたn−ヘキサン層は芒硝で脱
水後、40〜45℃水浴中で減圧下濃縮すると23gの
オイルが得られた。これを約30mlのn−ヘキサン
にとかし、あらかじめ2Kgのシリカゲルをn−ヘ
キサンでつめてあるカラムに吸着せしめ、n−ヘ
キサン:アセトン(95:5)で展開した。その結
果目的物質B−41Dを含有するフラクシヨンを
2.5得た。これらを前述と同様の条件で濃縮す
るとB−41Dの粗結晶が得られた。これをn−ヘ
キサン:酢酸エチル(20:1)に溶解後、室温に
放置し、析出する結晶を取し、B−41Dの精結
晶210mgを得た。
[Table] Example 3 Prepare the seed medium shown in Example 1, and add 600 ml of it.
was dispensed into 2000 ml Erlenmeyer flasks and sterilized. One loopful of B-41-146 strain was inoculated into this,
Culture was carried out at 28° C. for 48 hours, and the two 2000 ml Erlenmeyer flasks were transferred to a 30-jar famenta. Jiya Huamenta contains 4% glucose, 1% soy flour, 0.5% corn starch, 1% skim milk, 0.2% corn steep liquor,
Medium containing 0.3% NaCl and 0.05 % CaCO20
was prepared, the pH was adjusted to 7.2 to 7.5, and it was thoroughly sterilized. During the culture period, the temperature was 28℃ and the internal pressure was 0.5Kg/ cm2.
was held at After 3 days of culture, 0.01% DL-valine was added and cultured for an additional 5 days. Of the total production of group B-41 antibiotics, D accounted for 68% (weight ratio). When cultured under the same conditions without adding DL-valine, the proportion of B-41D remained at 35%.
PH of culture 20 obtained with addition of DL-valine
was adjusted to 3 with sulfuric acid, 1 kg of Celite was added, and the mixture was filtered under pressure to obtain a cake weighing approximately 3 kg. This was extracted with 15 parts of methanol and separated, 10 parts of water was added to the obtained methanol solution 15 parts, and extracted with 20 parts of n-hexane. The obtained n-hexane layer was dehydrated with Glauber's salt and concentrated under reduced pressure in a 40-45°C water bath to obtain 23 g of oil. This was dissolved in about 30 ml of n-hexane, adsorbed onto a column packed with 2 kg of silica gel in advance with n-hexane, and developed with n-hexane:acetone (95:5). As a result, a fraction containing the target substance B-41D was obtained.
Got 2.5. When these were concentrated under the same conditions as described above, crude crystals of B-41D were obtained. This was dissolved in n-hexane:ethyl acetate (20:1), left to stand at room temperature, and precipitated crystals were collected to obtain 210 mg of crystals of B-41D.

Claims (1)

【特許請求の範囲】 1 ストレプトマイセス属に属する抗生物質B−
41生産菌を培養してB−41D、E及びGを製造す
るに際し、バリン、イソ酪酸、イソ吉草酸、2−
ケトイソ吉草酸、イソカプロン酸、これら酸の塩
またはエステル、イソブタノール及びそのエステ
ルから選ばれた1種または2種以上を培地に添加
することを特徴とするB−41D、E及びGの製造
法。 2 B−41生産菌がストレプミセス属B−41−
146株である特許請求の範囲第1項記載の製造法。 3 B−41Dを製造するための特許請求の範囲第
2項記載の製造法。 4 ストレプトミセス属B−41−146株を、L−
またはDL−バリン、イソ酪酸、2−ケトイソ吉
草酸およびこれらの酸の塩またはエステルから選
ばれた1種または2種以上を添加した培地に培養
してB−41Dを製造する特許請求の範囲第1項記
載の製造法。
[Claims] 1. Antibiotic B- belonging to the genus Streptomyces
41 When producing B-41D, E and G by culturing production bacteria, valine, isobutyric acid, isovaleric acid, 2-
A method for producing B-41D, E and G, which comprises adding one or more selected from ketoisovaleric acid, isocaproic acid, salts or esters of these acids, isobutanol and esters thereof to the medium. 2 The B-41 producing bacterium is Strepmyces B-41-
146 strain according to claim 1. 3. The manufacturing method according to claim 2 for manufacturing B-41D. 4 Streptomyces genus B-41-146 strain, L-
or B-41D is produced by culturing in a medium supplemented with one or more selected from DL-valine, isobutyric acid, 2-ketoisovaleric acid, and salts or esters of these acids. The manufacturing method described in item 1.
JP17806181A 1981-11-06 1981-11-06 Preparation of antibiotic substance b-41d, e, and g Granted JPS5878594A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP17806181A JPS5878594A (en) 1981-11-06 1981-11-06 Preparation of antibiotic substance b-41d, e, and g

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17806181A JPS5878594A (en) 1981-11-06 1981-11-06 Preparation of antibiotic substance b-41d, e, and g

Publications (2)

Publication Number Publication Date
JPS5878594A JPS5878594A (en) 1983-05-12
JPS6366200B2 true JPS6366200B2 (en) 1988-12-20

Family

ID=16041918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP17806181A Granted JPS5878594A (en) 1981-11-06 1981-11-06 Preparation of antibiotic substance b-41d, e, and g

Country Status (1)

Country Link
JP (1) JPS5878594A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230047163A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047162A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047165A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047164A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8800986A1 (en) * 1985-07-27 1987-12-01 Pfizer Antiparasitic avermectin and milbemycin derivatives and process for their preparation.
US5840704A (en) * 1986-07-16 1998-11-24 Pfizer Inc. Antiparasitic agents and process for their preparation
US5234831A (en) * 1987-01-23 1993-08-10 Pfizer Inc Cultures for production of B avermectins
US5238848A (en) * 1987-01-23 1993-08-24 Pfizer Inc Cultures for production of avermectins
US5525506A (en) * 1987-01-23 1996-06-11 Pfizer Inc. Process for production of avermectins and cultures therefor
US5240850A (en) * 1987-10-23 1993-08-31 Pfizer Inc. Cultures for production of avermectin aglycones

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230047163A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047162A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047165A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member
KR20230047164A (en) 2020-08-06 2023-04-06 닛토덴코 가부시키가이샤 Reinforcing film, optical member and electronic member

Also Published As

Publication number Publication date
JPS5878594A (en) 1983-05-12

Similar Documents

Publication Publication Date Title
US4576961A (en) Antibiotic heterocyclic oxygen compounds and use
CA1335367C (en) Ks-506 compounds and process for the production thereof
JP2728406B2 (en) Method for producing anti-substance A / 16686 complex
JPS6366200B2 (en)
JPS6316120B2 (en)
CH624956A5 (en) METHOD FOR REMOVING IMPURITIES FROM CLAVULANIC ACID.
US2885433A (en) O-carbamyl-d-serine
EP0395106B1 (en) Demethylallosamidin and a process for production thereof
DE2652677C2 (en) Antibiotics 890A ↓ 1 ↓ and 890A ↓ 3 ↓, processes for their preparation, and antibacterial agents containing these antibiotics
EP0652205A2 (en) Moenomycin degradation products containing hydroxylated or oxidized lateral lipid chain and moenomycin analogs, process for preparing and their use
US4229534A (en) Acetylthienamycin production
DE3003359C2 (en)
DK144658B (en) PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC C-15003 P-4
US4165379A (en) N-acetyl thienamycin
JPS6024717B2 (en) antibiotic mycoplanesin
US4370266A (en) Mycoplanecin derivatives and their preparation
CA1108078A (en) Fermentation process
EP0055929B1 (en) Antibiotic c-19393 e5 and production thereof
JP2897834B2 (en) Method for producing avermectins A1a, A2a, B1a and B2a by fermentation and a new strain belonging to Streptomyces avermitilis
CH643298A5 (en) PROCESS FOR THE MANUFACTURE OF NEW ANTIBIOTICS.
JP2971204B2 (en) New substance WK-2955 and method for producing the same
US4009077A (en) Process for the preparation of phenopicolinic acid
EP0009363A1 (en) Method of separating cephalosporins
JP2858939B2 (en) Antibiotics AB3217A, AB3217B and AB3217C and their production
JPH0429356B2 (en)